Generic Name and Formulations:
Ocriplasmin 2.5mg/mL; per vial; soln for intravitreal inj after dilution; contains mannitol; preservative- and latex-free.
Indications for JETREA:
Treatment of symptomatic vitreomacular adhesion.
Give by intravitreal inj. 0.125mg (0.1mL of the diluted soln) once as a single dose to the affected eye.
For ophthalmic intravitreal inj only. Monitor for elevation in intraocular pressure immediately after inj. Monitor for decreased vision. Repeated administration in the same eye: not recommended. Treatment in the other eye is not recommended within 7 days of the initial inj. Pregnancy (Cat.C). Nursing mothers.
Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema; intraocular inflammation/infection/hemorrhage, increased intraocular pressure, yellowish vision.
Single-use vial (0.2mL)—1
Endocrinology Advisor Articles
- ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes
- Updated Clinical Practice Guidelines on Testosterone Therapy in Men With Hypogonadism
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Once-Daily Oral Contraceptive for Men Shows Promise
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Common Plant-Derived Oils May Contain Endocrine-Disrupting Chemicals
- Red Meat Consumption Linked to Insulin Resistance and Steatohepatitis
- Effect of High Androgen Levels on Cardiovascular Risk in Postmenopausal Women
- Fertility in Women Negatively Affected by Asthma Medications
- Glucocorticoid Use in COPD Does Not Increase Fracture Risk